Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension phase II open-label study of imatinib in Philadelphia chromosome-positive chronic myeloid leukemia in myeloid blast crisis
2005-001380-61Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in chronic myelogenous leukemia (CML), sponsored by Novartis. Primary endpoint: Overall survival. Started Mar 2007; status: completed.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2005-001380-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001380-61.